Picton Mahoney Asset Management Has $19.36 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX)

Picton Mahoney Asset Management trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 100,441 shares of the pharmaceutical company’s stock after selling 759 shares during the period. Vertex Pharmaceuticals accounts for 1.4% of Picton Mahoney Asset Management’s investment portfolio, making the stock its 23rd biggest position. Picton Mahoney Asset Management’s holdings in Vertex Pharmaceuticals were worth $19,359,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Kaizen Advisory LLC raised its position in shares of Vertex Pharmaceuticals by 147.3% during the 2nd quarter. Kaizen Advisory LLC now owns 601 shares of the pharmaceutical company’s stock valued at $102,000 after buying an additional 358 shares in the last quarter. Stratos Wealth Partners LTD. purchased a new position in Vertex Pharmaceuticals in the 3rd quarter worth $123,000. Sun Life Financial INC raised its position in Vertex Pharmaceuticals by 266.1% in the 2nd quarter. Sun Life Financial INC now owns 692 shares of the pharmaceutical company’s stock worth $118,000 after purchasing an additional 503 shares during the period. Flagship Harbor Advisors LLC purchased a new position in Vertex Pharmaceuticals in the 2nd quarter worth $125,000. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in Vertex Pharmaceuticals by 3,126.1% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 742 shares of the pharmaceutical company’s stock worth $126,000 after purchasing an additional 719 shares during the period. 93.51% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently commented on VRTX shares. Cantor Fitzgerald started coverage on shares of Vertex Pharmaceuticals in a research report on Monday, October 1st. They issued an “overweight” rating and a $217.00 target price on the stock. Piper Jaffray Companies decreased their target price on shares of Vertex Pharmaceuticals to $217.00 and set an “overweight” rating on the stock in a research report on Friday, October 26th. Argus lifted their target price on shares of Vertex Pharmaceuticals to $200.00 and gave the stock an “average” rating in a research report on Tuesday, August 28th. They noted that the move was a valuation call. Citigroup lifted their target price on shares of Vertex Pharmaceuticals from $203.00 to $206.00 and gave the stock a “buy” rating in a research report on Monday, July 30th. Finally, UBS Group lifted their target price on shares of Vertex Pharmaceuticals from $183.00 to $188.00 and gave the stock a “neutral” rating in a research report on Thursday, July 26th. Three equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company’s stock. Vertex Pharmaceuticals currently has an average rating of “Buy” and an average price target of $202.14.

Shares of Vertex Pharmaceuticals stock opened at $183.88 on Thursday. The firm has a market capitalization of $44.78 billion, a price-to-earnings ratio of 229.85, a PEG ratio of 1.74 and a beta of 1.61. Vertex Pharmaceuticals Incorporated has a 12-month low of $136.50 and a 12-month high of $194.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.59 and a current ratio of 3.71.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, October 24th. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.07. The business had revenue of $784.54 million for the quarter, compared to analyst estimates of $782.95 million. Vertex Pharmaceuticals had a net margin of 22.87% and a return on equity of 22.92%. During the same quarter last year, the firm earned $0.53 EPS. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 2.55 earnings per share for the current fiscal year.

In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 2,155 shares of the firm’s stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $175.36, for a total value of $377,900.80. Following the sale, the executive vice president now owns 48,907 shares of the company’s stock, valued at approximately $8,576,331.52. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP David Altshuler sold 2,125 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, August 28th. The shares were sold at an average price of $181.89, for a total transaction of $386,516.25. Following the sale, the executive vice president now directly owns 41,238 shares in the company, valued at approximately $7,500,779.82. The disclosure for this sale can be found here. In the last three months, insiders sold 27,425 shares of company stock worth $5,095,719. Insiders own 1.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Picton Mahoney Asset Management Has $19.36 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX)” was originally published by WKRB News and is the property of of WKRB News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.wkrb13.com/2018/11/08/picton-mahoney-asset-management-has-19-36-million-holdings-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Featured Story: What is dollar cost averaging (DCA)?

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply